Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 4
Abstract
Background and aims. Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-α/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. The importance of these IL28B variants for Argentine patients remains unknown. Material and methods. IL28B host genotypes (rs8099917 and rs12979860) were determined in a population of Argentine patients with European ancestry. Results were analyzed looking for their association with sustained virologic response (SVR) to PR therapy and compared with other baseline hosts’ biochemical, histological and virological predictors of response. Results. We studied 102 patients, 60% were men, and 40% of them were rs8099917 TT and 18% rs12979860 CC. Mean baseline serum HCV RNA was 1.673.092 IU/mL and mean F score was: 2.10 ± 1.18 (21% cirrhotic). SVR rate was higher in rs8099917 TT genotypes (55%) when compared to GT/GG (25%) (p = 0.002) and in rs1512979860 CC (64%) than in CT/TT (30%) (p = 0.004). The univariate analysis showed that rs8099917 TT (OR 3.7; 95 %CI 1.5-8.7; p = 0.002), rs12979860 CC (OR 4.6; 95%CI 1.5-13.7; p = 0.006), low viral load (OR 4.6; 95% CI 1.7-12.6; p = 0.002) and F0-2 (OR 8.5; 95% CI 2.3-30.6; p = 0.001) were significantly associated with SVR. In the multivariate analysis, rs12979860 CC, rs8099917 TT, viral load < 400.000 IU/mL and F0-2 were associated with SVR rates (p = 0.029, p = 0.012, p = 0.013 and p = 0.004, respectively). Conclusion. IL28B host genotypes should be added to baseline predictors of response to PR therapy in Latin American patients with European ancestry.
Authors and Affiliations
Ezequiel Ridruejo, Ángela Solano, Sebastián Marciano, Omar Galdame, Raúl Adrover, Daniel Cocozzella, Dreanina Delettieres, Alfredo Martínez, Adrián Gadano, Oscar Mandó, Marcelo Silva
Keywords
Related Articles
- EP ID EP78075
- DOI -
- Views 141
- Downloads 0
Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Introduction. The role of hepatitis C virus infection as a risk factor for the development and progression of chronic kidney disease in the general population remains unclear. Material and methods. A systematic review of...
Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program
Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy...
Insulin treatment of people with diabetes mellitus and chronic liver disease
Long term changes in liver histology following treatment of chronic hepatitis C virus
Background and aims. The histologic hallmarks of chronic HCV include inflammation and fibrosis. The impact of interferon therapy on liver histology was evaluated. Material and methods. The study population consisted of 3...
D-MELD does not predict post-liver transplantation survival: a single-center experience from Brazil
Background. The D-MELD score was designed to prevent donor-recipient matches with a high risk of unfavorable outcome. The main objective of the present study was to assess the predictive value of the DMELD score for 1-mo...